Overview

A Study to Determine the Efficacy, Safety, and Durability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration

Status:
RECRUITING

Trial end date:
2028-01-31

Target enrollment:

Participant gender:

Summary

This study is a Phase IIIb/IV, multicenter, randomized, two-arm, open-label 100-week study to investigate the efficacy, safety, and durability of intravitreal 6-mg faricimab administered at up to 24-week intervals in patients with neovascular age-related macular degeneration (nAMD) that are treatment-nave in the study eye.

Phase:

PHASE4

Details

Lead Sponsor:

Hoffmann-La Roche

Treatments:

faricimab